🚨 JUST IN: $EVMN
Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones
#SEC #stocks #investing #EVMN #Mergers
🔗 secwatch.observer
Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones
#SEC #stocks #investing #EVMN #Mergers
🔗 secwatch.observer
November 4, 2026 at 11:12 PM
🚨 JUST IN: $EVMN
Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones
#SEC #stocks #investing #EVMN #Mergers
🔗 secwatch.observer
Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones
#SEC #stocks #investing #EVMN #Mergers
🔗 secwatch.observer
🚨 $EVMN
On November 4, 2026, the Company issued a press release announcing the License Agreement.
On November 4, 2026, the Company issued a press release announcing the License Agreement.
SEC Filing: EVMN
Click to view the official SEC document.
www.sec.gov
November 4, 2026 at 10:48 PM
🚨 $EVMN
On November 4, 2026, the Company issued a press release announcing the License Agreement.
On November 4, 2026, the Company issued a press release announcing the License Agreement.
SELL $EVMN (EVMN.N) [StockDilution] Private Placement; Announced @ 22:10:00Z
November 4, 2026 at 10:10 PM
SELL $EVMN (EVMN.N) [StockDilution] Private Placement; Announced @ 22:10:00Z
Evommune seeks 'JAK-like efficacy' in $1.1B Hinova deal for glue degrader #$EVMN firstwordpharma.com/story/8361557
November 5, 2026 at 11:28 PM
Evommune seeks 'JAK-like efficacy' in $1.1B Hinova deal for glue degrader #$EVMN firstwordpharma.com/story/8361557
🚨 $EVMN
On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
SEC Filing: EVMN
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 11:32 AM
🚨 $EVMN
On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
#EVMN Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
https://www.stocktitan.net/news/EVMN/evommune-announces-webcast-discussing-evo570-and-its-expanding-hpyu4ze7syse.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-announces-webcast-discussing-evo570-and-its-expanding-hpyu4ze7syse.html?utm_source=stocktitan-bluesky&utm_medium=social
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 5, 2026 at 11:30 AM
#EVMN Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
https://www.stocktitan.net/news/EVMN/evommune-announces-webcast-discussing-evo570-and-its-expanding-hpyu4ze7syse.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-announces-webcast-discussing-evo570-and-its-expanding-hpyu4ze7syse.html?utm_source=stocktitan-bluesky&utm_medium=social
#EVMN Evommune Announces $30 Million Private Placement
https://www.stocktitan.net/news/EVMN/evommune-announces-30-million-private-36j38cwq3ny6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-announces-30-million-private-36j38cwq3ny6.html?utm_source=stocktitan-bluesky&utm_medium=social
Evommune Announces $30 Million Private Placement
Evommune (NYSE: EVMN) entered into a securities purchase agreement for a private placement expected to raise approximately $30 million.The company agreed to sell 4,966,889 common shares at $6.04 each to healthcare institutional investors, including both new and existing investors. Expected gross proceeds are before transaction-related expenses. Closing is expected on or about November 6, 2026, subject to customary closing conditions. Evommune intends to use the net proceeds to advance clinical development programs, including EVO570, its newly in-licensed oral VAV1-directed molecular glue degrader, and for general corporate purposes.
www.stocktitan.net
November 4, 2026 at 10:10 PM
#EVMN Evommune Announces $30 Million Private Placement
https://www.stocktitan.net/news/EVMN/evommune-announces-30-million-private-36j38cwq3ny6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-announces-30-million-private-36j38cwq3ny6.html?utm_source=stocktitan-bluesky&utm_medium=social
#EVMN Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from H…
https://www.stocktitan.net/news/EVMN/evommune-enters-into-agreement-to-in-license-evo570-a-potential-best-euu5np22wfuk.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-enters-into-agreement-to-in-license-evo570-a-potential-best-euu5np22wfuk.html?utm_source=stocktitan-bluesky&utm_medium=social
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 4, 2026 at 10:02 PM
#EVMN Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from H…
https://www.stocktitan.net/news/EVMN/evommune-enters-into-agreement-to-in-license-evo570-a-potential-best-euu5np22wfuk.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-enters-into-agreement-to-in-license-evo570-a-potential-best-euu5np22wfuk.html?utm_source=stocktitan-bluesky&utm_medium=social
$EQNR-1 $CRCL-1 $DXCM-1 $FAST-1 $ST-1 $LUNR-1 $TEM-1 $CNQ-1 $XYL-1 $COO-1 $XLK-1 $NCNO-1 $IBRX-1 $TMUS-1 $IQV-1 $OSCR-1 $P-1 $JPM-1 $INVH-1 $XP-1 $SMCI-1 $ASST-1 $LTGO-1 $EXC-1 $BMNU-1 $V-1 $GKOS-1 $T-1 $EVMN-1 $MIR-1 $NIQ-1 $OXY-1 $CF-1 $ICLR-1 $STNE-1 $SPDN-1
October 28, 2026 at 8:10 PM
$EQNR-1 $CRCL-1 $DXCM-1 $FAST-1 $ST-1 $LUNR-1 $TEM-1 $CNQ-1 $XYL-1 $COO-1 $XLK-1 $NCNO-1 $IBRX-1 $TMUS-1 $IQV-1 $OSCR-1 $P-1 $JPM-1 $INVH-1 $XP-1 $SMCI-1 $ASST-1 $LTGO-1 $EXC-1 $BMNU-1 $V-1 $GKOS-1 $T-1 $EVMN-1 $MIR-1 $NIQ-1 $OXY-1 $CF-1 $ICLR-1 $STNE-1 $SPDN-1
🚨 $EVMN
Pena Luis C. (President & CEO) reported special transactions (Non-P/S).
Pena Luis C. (President & CEO) reported special transactions (Non-P/S).
SEC Filing: EVMN
Click to view the official SEC document.
www.sec.gov
October 15, 2026 at 8:29 PM
🚨 $EVMN
Pena Luis C. (President & CEO) reported special transactions (Non-P/S).
Pena Luis C. (President & CEO) reported special transactions (Non-P/S).
Evommune #$EVMN , Aethlon Medical #$AEMD , Nektar #$NKTR and Turn Therapeutics #$TTRX are pushing atopic dermatitis treatment beyond type 2 inflammation. Our Eczema Awareness Month look at four AD stocks:
prismmarketview.com/eczema-aware...
prismmarketview.com/eczema-aware...
October 9, 2026 at 1:30 PM
Evommune #$EVMN , Aethlon Medical #$AEMD , Nektar #$NKTR and Turn Therapeutics #$TTRX are pushing atopic dermatitis treatment beyond type 2 inflammation. Our Eczema Awareness Month look at four AD stocks:
prismmarketview.com/eczema-aware...
prismmarketview.com/eczema-aware...
🚨 $EVMN
On October 1, 2026, Evommune, Inc. issued a press release titled "Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress". A copy of the press release is furnished herewith as Exhibi...
On October 1, 2026, Evommune, Inc. issued a press release titled "Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress". A copy of the press release is furnished herewith as Exhibi...
SEC Filing: EVMN
Click to view the official SEC document.
www.sec.gov
October 1, 2026 at 12:02 PM
🚨 $EVMN
On October 1, 2026, Evommune, Inc. issued a press release titled "Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress". A copy of the press release is furnished herewith as Exhibi...
On October 1, 2026, Evommune, Inc. issued a press release titled "Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress". A copy of the press release is furnished herewith as Exhibi...
🚨 $EVMN
On September 23, 2026, Evommune, Inc. issued a press release titled "Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress". A copy of the press release is furnished herewith as Exhibit ...
On September 23, 2026, Evommune, Inc. issued a press release titled "Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress". A copy of the press release is furnished herewith as Exhibit ...
SEC Filing: EVMN
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 8:09 PM
🚨 $EVMN
On September 23, 2026, Evommune, Inc. issued a press release titled "Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress". A copy of the press release is furnished herewith as Exhibit ...
On September 23, 2026, Evommune, Inc. issued a press release titled "Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress". A copy of the press release is furnished herewith as Exhibit ...
🚨 $EVMN
On September 15, 2026, Evommune, Inc. posted an updated corporate presentation on the “Company Info” page of the Company’s website at https://ir.evommune.com/company-info/presentations.
On September 15, 2026, Evommune, Inc. posted an updated corporate presentation on the “Company Info” page of the Company’s website at https://ir.evommune.com/company-info/presentations.
SEC Filing: EVMN
Click to view the official SEC document.
www.sec.gov
September 15, 2026 at 12:31 PM
🚨 $EVMN
On September 15, 2026, Evommune, Inc. posted an updated corporate presentation on the “Company Info” page of the Company’s website at https://ir.evommune.com/company-info/presentations.
On September 15, 2026, Evommune, Inc. posted an updated corporate presentation on the “Company Info” page of the Company’s website at https://ir.evommune.com/company-info/presentations.
Evommune $EVMN: Leerink Partners lowered its price target from $28.00 to $22.00 and maintained its Outperform rating.
https://fundspec.ai/s/EVMN/analysts
Set a price alert once and let it watch the tape for you.
https://fundspec.ai/s/EVMN/analysts
Set a price alert once and let it watch the tape for you.
September 9, 2026 at 4:15 PM
Evommune $EVMN: Leerink Partners lowered its price target from $28.00 to $22.00 and maintained its Outperform rating.
https://fundspec.ai/s/EVMN/analysts
Set a price alert once and let it watch the tape for you.
https://fundspec.ai/s/EVMN/analysts
Set a price alert once and let it watch the tape for you.
🚨 $EVMN
On September 8, 2026, Evommune, Inc. issued a press release titled "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
On September 8, 2026, Evommune, Inc. issued a press release titled "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
SEC Filing: EVMN
Click to view the official SEC document.
www.sec.gov
September 9, 2026 at 10:01 AM
🚨 $EVMN
On September 8, 2026, Evommune, Inc. issued a press release titled "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
On September 8, 2026, Evommune, Inc. issued a press release titled "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
#EVMN Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
https://www.stocktitan.net/news/EVMN/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-tng22b0c10js.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-tng22b0c10js.html?utm_source=stocktitan-bluesky&utm_medium=social
A 121-person eczema trial missed its goal. Evommune will not advance the drug.
Evommune will continue EVO756 migraine-prophylaxis development and plans EVO301's Phase 2b trial for mid-2027 after positive Phase 2a data.
www.stocktitan.net
September 8, 2026 at 9:43 PM
#EVMN Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
https://www.stocktitan.net/news/EVMN/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-tng22b0c10js.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-tng22b0c10js.html?utm_source=stocktitan-bluesky&utm_medium=social
Market News Alert | Sep 8, 2026 | 17:43 ET
EVMN (Evommune)
EVO756 Fails Phase 2b Atopic Dermatitis Trial; Evommune Halts AD Program
💰 Current price: $9.50
Chart reflects closing price
Importance Score: 9/10 | Sentiment: Negative
We peeled this one open so you don't slip.
EVMN (Evommune)
EVO756 Fails Phase 2b Atopic Dermatitis Trial; Evommune Halts AD Program
💰 Current price: $9.50
Chart reflects closing price
Importance Score: 9/10 | Sentiment: Negative
We peeled this one open so you don't slip.
September 8, 2026 at 9:52 PM
Market News Alert | Sep 8, 2026 | 17:43 ET
EVMN (Evommune)
EVO756 Fails Phase 2b Atopic Dermatitis Trial; Evommune Halts AD Program
💰 Current price: $9.50
Chart reflects closing price
Importance Score: 9/10 | Sentiment: Negative
We peeled this one open so you don't slip.
EVMN (Evommune)
EVO756 Fails Phase 2b Atopic Dermatitis Trial; Evommune Halts AD Program
💰 Current price: $9.50
Chart reflects closing price
Importance Score: 9/10 | Sentiment: Negative
We peeled this one open so you don't slip.
#$EVMN shares fell after hours as EVO756 missed its Phase 2b atopic dermatitis goal. The company will not advance the drug in eczema and shifts focus to EVO301. notreload.xyz/xy/evommune-...
Evommune Stock Drops After EVO756 Eczema Trial Miss
The company will not advance the drug in eczema and shifts focus to EVO301.
notreload.xyz
September 8, 2026 at 10:05 PM
#$EVMN shares fell after hours as EVO756 missed its Phase 2b atopic dermatitis goal. The company will not advance the drug in eczema and shifts focus to EVO301. notreload.xyz/xy/evommune-...
$VNDA-1 $UPS-1 $PCG-1 $ALHC-1 $CLF-1 $KOLD-1 $EFA-1 $ARLO-1 $TRI-1 $TTEK-1 $EVMN-1 $GLDM-1 $AESI-1 $RAM-1 $CCI-1 $PENN-1 $ESAB-1 $JBL-1 $BOIL-1 $SEI-1 $MWH-1 $PSKY-1 $ARKK-1 $RCAT-1 $AG-1 $XBI-1 $PGY-1 $NMAX-1 $BILL-1 $AN-1 $SPRY-1 $MRK-1 $BABA-1 $WRBY-1 $KD-1
August 20, 2026 at 8:10 PM
$VNDA-1 $UPS-1 $PCG-1 $ALHC-1 $CLF-1 $KOLD-1 $EFA-1 $ARLO-1 $TRI-1 $TTEK-1 $EVMN-1 $GLDM-1 $AESI-1 $RAM-1 $CCI-1 $PENN-1 $ESAB-1 $JBL-1 $BOIL-1 $SEI-1 $MWH-1 $PSKY-1 $ARKK-1 $RCAT-1 $AG-1 $XBI-1 $PGY-1 $NMAX-1 $BILL-1 $AN-1 $SPRY-1 $MRK-1 $BABA-1 $WRBY-1 $KD-1
This is gibberish and infantile. Amazes me how anyone beyond tech bros would take it seriously.
m.youtube.com/watch?v=EvmN...
m.youtube.com/watch?v=EvmN...
Curtis Yarvin on a bench outside the White House
YouTube video by Nimrod Kamer
m.youtube.com
June 2, 2025 at 11:55 PM
This is gibberish and infantile. Amazes me how anyone beyond tech bros would take it seriously.
m.youtube.com/watch?v=EvmN...
m.youtube.com/watch?v=EvmN...
